Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Hemogenyx Pharmaceuticals PLC

Healthcare GB HEMO

722.0GBX
-2.0(0.28%)

Last update at 2026-06-05T15:35:00Z

Day Range

719.00750.00
LowHigh

52 Week Range

124.001800.00
LowHigh

Fundamentals

  • Previous Close 724.00
  • Market Cap62.04M
  • Volume32722
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.98441M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.31

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -5.62548M -6.69649M -3.98698M -5.10831M -2.09502M
Minority interest 0.00630M 0.00581M 0.00767M 0.00908M -0.01516M
Net income -5.61918M -6.69068M -4.34814M -7.52274M -2.11546M
Selling general administrative 4.74M 4.91M 0.94M 1.40M 0.62M
Selling and marketing expenses - 4.91M - - 0.00422M
Gross profit -0.63928M -0.64568M -2.59976M -0.28365M -0.35072M
Reconciled depreciation 0.64M 0.65M 0.20M 0.13M 0.11M
Ebit -5.35392M -6.38050M 4.00M -2.70275M -2.15039M
Ebitda -4.71464M -5.73482M -3.42288M -2.55846M -1.95503M
Depreciation and amortization 0.64M 0.65M -7.42042M 0.14M 0.20M
Non operating income net other - - - - -
Operating income -5.72669M -5.55855M 4.00M -2.70275M -2.15039M
Other operating expenses 5.73M 5.56M 5.53M 2.83M 2.22M
Interest expense 0.27M 0.32M 0.00003M 2.60M 0.03M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.02M 0.09M 0.01M 0.02M 0.00336M
Net interest income -0.24839M -0.23065M 0.01M -2.57743M -0.02987M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - -0.00582M 0.36M 2.41M 0.02M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 5.09M 4.91M 2.93M 2.55M 1.87M
Cost of revenue 0.64M 0.65M 2.60M 0.28M 0.35M
Total other income expense net 0.10M -1.13794M -7.98453M -2.40556M 0.06M
Discontinued operations - - - - -
Net income from continuing ops -5.62548M -6.69649M -3.98698M -5.10831M -2.09502M
Net income applicable to common shares - - - -5.09923M -2.08222M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 4.21M 6.11M 7.09M 8.52M 2.66M
Intangible assets 0.48M 0.47M 0.44M 0.44M 0.25M
Earning assets - - - - -
Other current assets 0.67M 0.92M - 0.30M 0.10M
Total liab 3.36M 3.32M 3.85M 0.35M 1.79M
Total stockholder equity 0.90M 2.82M 3.28M 8.19M 0.89M
Deferred long term liab - - - - 0.22M
Other current liab -0.37198M -0.19579M 0.05M 0.05M 0.05M
Common stock 0.04M 11.76M 9.80M 9.80M 4.34M
Capital stock 0.04M 11.76M 9.80M 9.80M 4.34M
Retained earnings -35.58181M -23.80473M -17.11406M -13.13474M -8.03551M
Other liab - - - - 0.00000M
Good will - 0.03M - - -
Other assets - - - 0.14M 0.22M
Cash 0.16M 1.25M 2.53M 6.84M 1.81M
Cash and equivalents - - - - -
Total current liabilities 1.16M 0.65M 0.75M 0.35M 1.78M
Current deferred revenue - -0.00038M - - -
Net debt 2.46M 1.70M 0.89M -6.83082M -0.18417M
Short term debt 0.85M 0.55M 0.32M 0.01M 1.62M
Short long term debt - - 0.00000M 0.00000M 1.58M
Short long term debt total 2.62M 2.95M 3.42M 0.01M 1.63M
Other stockholder equity 35.37M 19.94M 10.59M 11.53M 4.59M
Property plant equipment - - - 0.80M 0.27M
Total current assets 0.84M 2.17M 2.59M 7.14M 1.92M
Long term investments - - - - -
Net tangible assets - - - 7.75M 0.64M
Short term investments - - - - -
Net receivables 0.00786M 0.00107M 0.00015M 0.30M 0.06M
Long term debt - - - - 0.00000M
Inventory - - - - -
Accounts payable 0.68M 0.30M 0.37M 0.30M 0.11M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.07M -5.07075M - - -0.21321M
Additional paid in capital - - - - -
Common stock total equity - - - - 4.34M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.17M 0.15M 0.14M 0.14M 0.22M
Deferred long term asset charges - - - - -
Non current assets total 3.37M 3.94M 4.50M 1.38M 0.75M
Capital lease obligations 2.62M 2.95M 3.42M 0.01M 0.05M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -0.00173M -0.03194M -0.42025M -0.93895M -0.16968M
Change to liabilities - - 0.00000M 0.30M -0.03574M
Total cashflows from investing activities -0.02490M -0.03194M - -0.93895M -0.16968M
Net borrowings - - - -3.22236M 0.42M
Total cash from financing activities 3.08M 4.45M -0.11014M 8.78M 3.21M
Change to operating activities - - - - 0.00062M
Net income -5.61918M -6.69068M -3.98698M -5.10831M -2.09502M
Change in cash -1.08834M -1.28516M -4.30821M 5.03M 1.31M
Begin period cash flow 1.25M 2.53M 6.84M 1.81M 0.50M
End period cash flow 0.16M 1.25M 2.53M 6.84M 1.81M
Total cash from operating activities -4.11690M -6.10557M -2.91060M -2.62730M -1.79840M
Issuance of capital stock 3.71M 5.09M - 0.00000M 3.18M
Depreciation 0.64M 0.65M 0.20M 0.13M 0.11M
Other cashflows from investing activities -0.01161M 0.09M - -0.12095M 0.00336M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.00264M 0.00447M - -0.19668M -0.02140M
Sale purchase of stock - - - - 3.18M
Other cashflows from financing activities -0.63504M -0.63877M -0.42025M 11.96M 0.03M
Change to netincome - - 0.63M 2.24M 0.23M
Capital expenditures 0.01M 0.12M 0.43M 0.82M 0.17M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.60M -0.83360M 0.24M 0.10M -0.05651M
Stock based compensation 0.34M 0.00024M 0.02M 0.15M 0.36M
Other non cash items 0.26M 0.77M 0.62M 2.12M 0.03M
Free cash flow -4.13018M -6.22286M -3.33955M -3.44530M -1.97145M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
HEMO
Hemogenyx Pharmaceuticals PLC		 -2.0 0.28% 722.00 - - - 8.49 -3.6239
GNS
Genus PLC		 - -% 2274.00 36.08 26.18 2.53 3.46 2.92 15.38
ONT
Oxford Nanopore Technologies Ltd		 -9.7 6.93% 130.30 - - 4.71 2.50 4.23 -8.8899
OXB
Oxford BioMedica PLC		 30.00 5.00% 630.00 - 208.33 4.05 7.60 4.42 308.96
AVCT
Avacta Group PLC		 1.50 2.14% 71.50 - - 2849.46 1929.84 2525.51 -12.0368

Reports Covered

Stock Research & News

View All

Profile

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of treatments for blood cancer. The company's lead product candidate is the HG-CT-1 therapy for the treatment of relapsed or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat viral infections derived and for certain cancer and neurological conditions; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and therapies for the improvement of bone marrow and blood stem cell transplant procedures. Hemogenyx Pharmaceuticals Plc was incorporated in 2013 and is headquartered in London, the United Kingdom.

Hemogenyx Pharmaceuticals PLC

6 Heddon Street, London, United Kingdom, W1B 4BT

Key Executives

Name Title Year Born
Dr. Vladislav Sandler Ph.D. Co-Founder, CEO & Director NA
Ms. Alexis M. Sandler J.D. Independent Co-Founder & Non-Exec. Director NA
Mr. Andrew Wright Financial Controller & Company Sec. NA
Dr. Koen Van Besien M.D., Ph.D. Clinical Advisor & Medical Director NA
Dr. Vladislav Sandler Ph.D. Co-Founder, CEO & Director 1965
Ms. Alexis M. Sandler J.D. Independent Co-Founder & Non-Executive Director 1976
Mr. Ben Harber Company Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions